Science
George Kumar Neuroblastoma Cells Oncogene Cancer Research Lung Cancer Bassam Sonbol
Photo: Depositphotos

Bassam Sonbol: Randomized Phase II Trial of Pazopanib vs Placebo in Extrapancreatic NETs

Bassam Sonbol, Oncologist at Mayo Clinic Arizona, shared a post on X:

“Alliance A021202 (Bergsland et al, JCO). Randomized phase II of pazopanib vs placebo in extrapancreatic NETs (epNET).

PFS improved (11.8 vs 7.6 mo, HR 0.54).

No OS benefit. More toxicity plus on-study deaths.

N=171, mostly midgut (75%). PFS primary endpoint by blinded central review. Crossover allowed (49 pts from placebo). Median f/u: 61 mo.”

Bassam Sonbol: Randomized Phase II Trial of Pazopanib vs Placebo in Extrapancreatic NETs

Title: Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202)

Authors: Emily K. Bergsland, Susan Geyer, Timothy R. Asmis, Spencer C. Behr, J. Philip Kuebler, Priya Kumthekar, Gina Mazza, Michael L. Maitland, Donna Niedzwiecki, Andrew B. Nixon, Lawrence Howard Schwartz, Jonathan R. Strosberg, Alan P. Venook, Eileen M. O’Reilly, Jeffrey A. Meyerhardt

Read The Full Article at JCO Oncology.

Bassam Sonbol: Randomized Phase II Trial of Pazopanib vs Placebo in Extrapancreatic NETs

More Posts Featuring NETs.

 

Alan P Venook Alliance A021202 Andrew B. Nixon Bassam Sonbol cancer Donna Niedzwiecki Eileen M. O'Reilly Emily K. Bergsland extrapancreatic NETs Gina Mazza J. Philip Kuebler Jeffrey A Meyerhardt Jonathan R. Strosberg Lawrence Howard Schwartz Michael L. Maitland NETs OncoDaily Oncology Priya Kumthekar Spencer C. Behr Susan Geyer Timothy R. Asmis